The performance of companies tied to Sildenafil's history presents a challenging investment scenario . While the initial boom generated substantial returns , generic copies have significantly diminished revenue. Investing in associated pharmaceutical businesses now requires a discerning assessment of proprietary protection , evolving patient trends